Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1127749

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: BioMarin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the progress of talks on procuring medicines between the NHS and Bio Marin.
tabling member constituency	Gloucester
tabling member printed	Richard Graham
uin	256971
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>We have made no such assessment. Discussions about commercial agreements for medicines are rightly held between NHS England as an independent body and the manufacturer concerned. The Department plays no role in such discussions.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:48:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	3990 label Biography information for Richard Graham

1127754

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his timescale is for (a) implementing and (b) completing NHS England’s planned restructuring of haemoglobinopathy services; and if he will make a statement.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	256972
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256973 256974 257011 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson

1127755

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of NHS England’s planned restructuring of haemoglobinopathy services on (a) equitable access to services, (b) access to the most effective treatments, (c) access to highly specialised care and (d) quality of care in community-based settings for patients with sickle cell disease.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	256973
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256972 256974 257011 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson

1127756

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish impact assessments of the potential effects of NHS England’s planned restructuring of haemoglobinopathy services on treatment of (a) all haemoglobinopathies and (b) sickle cell disease.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	256974
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256972 256973 257011 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson

1127772

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the review of the methods for the NICE Technology Appraisal Programme referred to in the 2019 voluntary scheme for branded medicines pricing and access will include support for earlier patient access to innovative medicines.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	257056
answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve patient organisations and other relevant stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing and Access sets out the Department’s expectation that that any future changes to NICE methods and processes would support faster adoption of the most clinically and cost effective medicines. Additional detail and more information will be made available on the NICE website in due course.</p><p>The 2019 Voluntary Scheme also states that NICE will adopt the principle of appraisal timelines for non-oncology treatments matching the faster timescales for oncology treatments, subject to the evidence base for the product being sufficiently developed to enable a NICE appraisal with the same level of rigour and certainty as would be expected currently.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:52:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	4398 label Biography information for Chris Green

1127796

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to tackle falling numbers of GPs in England.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	256914
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>The NHS Long Term Plan made a clear commitment to the future of general practice, with primary and community care set to receive at least £4.5 billion more in real terms a year by 2023/24. Spend on these services will grow faster than the rising National Health Service budget. Since the launch of the NHS Long Term Plan, NHS England and the British Medical Association’s General Practitioners (GP) Committee have agreed a five-year GP (General Medical Services) contract framework from 2019/20. The new contract framework will be essential to deliver the ambitions set out in the NHS Long Term Plan through strong general practice services. The contract confirmed that NHS England will now extend a number of general practice programmes until 2023/24 to help deliver against the commitment to 5,000 additional doctors in general practice.</p><p> </p><p>NHS England and Health Education England (HEE) are working together with the profession to increase the GP workforce. This includes measures to boost recruitment, address the reasons why GPs are leaving the profession, and encourage GPs to return to practice.</p><p> </p><p>Further plans to support delivery will be set out in the final NHS workforce implementation plan due to be published later this year.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 04/06/2019 16:30:03 answering member 4455 label Biography information for Seema Kennedy
tabling member	308 label Biography information for Mr Jim Cunningham

1127797

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of standard 10-minute appointments with GPs.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	256915
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>No specific work has been done centrally to assess the effectiveness of the standard 10 minute consultation. However, there is no contractual obligation regarding the length of appointments in general practice.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 04/06/2019 16:30:35 answering member 4455 label Biography information for Seema Kennedy
tabling member	308 label Biography information for Mr Jim Cunningham

1127885

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he last made an assessment of the effectiveness of key performance indicators for NHS dental practices.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	257007
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>NHS England is responsible for the commissioning of dental services and performance management of contracts held. NHS England looks at and update key dental performance indicators as a continuous improvement process. They are prepared by the NHS Business Services Agency and have a formal review annually. The indicators are shared with National Health Service dental providers to assist them in delivering a high quality service to patients. Examples of the information provided can be found on the NHS Business Services Agency website at the following link:</p><p><a href="https://www.nhsbsa.nhs.uk/dental-data" target="_blank">https://www.nhsbsa.nhs.uk/dental-data</a></p><p> </p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 04/06/2019 16:28:20 answering member 4455 label Biography information for Seema Kennedy
tabling member	1533 label Biography information for Dame Diana Johnson

1127888

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 September 2016 to Question 45638, on sickle cell disease screen positive babies, if he will publish the data for (a) England, (b) each Public Health England sub-region and (c) each antenatal screening provider for each year since 2009-10.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	257009
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>Data on the number of sickle cell disease (SCD) babies born in England from 2010/11 are available to view here at the following link:</p><p><a href="https://www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-data-trends-and-performance-analysis" target="_blank">https://www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-data-trends-and-performance-analysis</a></p><p>Data prior to 2010/11 is available regionally in the National Health Service Sickle Cell and Thalassaemia Screening Programme archived reports at the following link:</p><p><a href="https://webarchive.nationalarchives.gov.uk/20150528151022/http:/sct.screening.nhs.uk/data-reports" target="_blank">https://webarchive.nationalarchives.gov.uk/20150528151022/http://sct.screening.nhs.uk/data-reports</a></p><p>From 2015/16 data is published by four regions and is reflected in the attached table.</p><p> </p><p>Data on the number of SCD babies born in England is publicly available. However, data for 2017/18 is not yet available but is due to be published at the end of 2019. Data for each antenatal screening provider is not available.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 04/06/2019 16:26:26 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name PQ257009 table formatted.docx title Number of babies with sickle cell 2009-17
tabling member	1533 label Biography information for Dame Diana Johnson

1127890

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Admissions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the latest Hospital Admitted Patient Care Activity data published in NHS Digital’s Hospital Episode Statistics data series, if he will publish the admissions data on sickle cell disorders (D57) for each (a) NHS England region and (b) Indices of Multiple Deprivation decile.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	257011
answer	answer is ministerial correction date of answer 04/06/2019 answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256972 256973 256974 question first answered 04/06/2019 16:13:21 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx title FAE sickle cell NHS England table
tabling member	1533 label Biography information for Dame Diana Johnson